Option chain shows key data for Tianneng Power Intl's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Tianneng Power Intl.

Tianneng Power Intl (OTC:TIANF) Stock, Option Chain

Tianneng Power International Ltd is an electronic components company. It operates through two business segments: manufacturing business and trading. The company is primarily engaged in manufacturing and selling of lead-acid batteries and battery-related accessories including motive, solar, and wind-powered batteries, lithium battery products, electrical bicycle batteries, and special-purpose batteries mainly used for electrical vehicles, and energy storage battery, among others. A vast majority of revenue is generated by the company's sale of batteries and battery-related accessories segment, and the company earns most of its revenue in The People's Republic of China.

TIANNENG POWER INTL LTD by Tianneng Power International Limited

Tianneng Power International Ltd

Jefferies analyst David Stanton downgrades Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) from Buy to Hold.

News

Downgrades

Analyst Ratings

MESO

Jefferies Downgrades Mesoblast to Hold

Despegar.com, Corp. (NYSE:<a href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) ("Despegar" or the "Company"), Latin America's leading travel technology company, today announced that it has entered into a definitive merger agreement ("the Agreement") to be acquired by Prosus (Euronext: PRX), a leading global technology company for $19.50 per share in an all cash transaction (the "Transaction"), representing an enterprise value of approximately $1.7 billion for Despegar.
The transaction price represents a premium of approximately 34% over the volume weighted average price of Despegar's share price for the 90 trading days ending on December 20, 2024.
Despegar's Board of Directors has approved the Agreement and has resolved to recommend that Despegar shareholders vote in favor of the adoption of the Agreement and the approval of the merger contemplated thereby. This approval follows the unanimous recommendation of a transaction committee of the Board of Directors comprised solely of independent directors that was formed in connection with the transaction

DESP

Despegar to Be Acquired by Prosus for $1.7B in Cash Deal

Needham analyst Joseph Stringer reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) from Hold to Hold.

Reiteration

LXRX

Needham Reiterates Hold on Lexicon Pharmaceuticalsto Hold

Compass Point analyst Dominick Gabriele initiates coverage on NCR Atleos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Buy rating and announces Price Target of $57.

Price Target

Initiation

NATL

Compass Point Initiates Coverage On NCR Atleos with Buy Rating, Announces Price Target of $57

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintains the price target from $20 to $20.

Upgrades

ACRS

HC Wainwright & Co. Upgrades Aclaris Therapeutics to Buy, Maintains Price Target to $20

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Buy and maintains $18 price target.

VNDA

HC Wainwright & Co. Reiterates Buy on Vanda Pharma, Maintains $18 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $69 price target.

RYTM

HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $69 Price Target

Market-Moving Exclusives

Exclusives

TELO

EXCLUSIVE: Telomir Pharmaceuticals Tells Benzinga Co. Confirms Copper-Binding Capabilities Of Telomir-1 And Expands Pipeline Into Wilson's Disease

Castellum, Inc. (NYSE-American: CTM) ("Castellum"), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that its <a href="https://www.globenewswire.com/Tracker?data=2uLrI8261QtiQmeyEX_gy6JpQ-moKeUMas7MX0KiELEefnH75OHV-JXUfPsv_zKI7gHoXxkBqsvA_eImOxN3D6G4PL5vSPCM60jU0LeJn-vqxAiMc5Hvq23f7HgN9H_j">subsidiary Specialty Systems, Inc.,</a> teaming with Castellum's other two subsidiaries <a href="https://www.globenewswire.com/Tracker?data=xuSy8FtCDO83pGRtqv3Bvd1mPpu7go0e-GbTqJOQfJpOv_sGIz-OJqLYw2ishXp8SNb4c4XnqbhR6CDFldnrtW6jI5X0Ly8kGJnXmWf_r7srd0t2OloOpVJX64Fh8CLU">Corvus Consulting, LLC</a> and <a href="https://www.globenewswire.com/Tracker?data=k8X5vM0eJAl01EJ9rJycnEmDk9yQVQVWU5kbUoIek9XS_3bxyu5GYFX64I44ybWTUYMcTU2iovmCpcKa02R-MD1goOgkN92qMYL4z1wzHMwClXsrY-NBB5mNeW7suWDSQclfL1E3M0ECNAUCnxh1Kg==">Global Technology and Management Resources, Inc.,</a> was awarded all four unrestricted domains upon which it submitted proposals. This award is in addition to the three small business domains the Castellum team has already been awarded on One Acquisition Solution for Integrated Services Plus ("OASIS+").
OASIS+ is a suite of government-wide, multi-award contracts designed to support federal agencies' procurement requirements for services-based solutions. With a potential ten-year performance period and no ceiling value, OASIS+ represents a significant opportunity for the Castellum team to expand its support to federal customers.

Government

Regulations

Castellum Secures Major Federal Contract Awards Through OASIS+ Program

GPUS

Hyperscale Data Secures Financing Agreement For Up To $25M In Series G Convertible Preferred Stock

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $7 price target.

RMTI

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $7 Price Target

On Monday, Telomir Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said.
Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's strong copper-binding affinity, enabling precise regulation of copper metabolism and interaction with essential ions.
According to the company, these findings position Telomir-1 as a potential breakthrough therapy for Wilson's disease, a rare disorder caused by ATP7B mutations leading to toxic copper buildup in vital organs.
Offering a safer alternative to current treatments, which have significant side effects and require lifelong adherence, Telomir-1 targets the disease's root cause and may qualify for orphan drug designation.
Telomir is also advancing Telomir-1's therapeutic potential in related areas, including Type 2 diabetes and age-related diseases.
The company is optimizing GMP-grade production for IND-enabling studies scheduled for second quarter of 2025, with an IND submission planned for the fourth quarter and first-in-human clinical trials expected by mid-2026. Efforts also include securing an INAD for pets and exploring Telomir-1's dual applications in human and veterinary medicine.
In line with its ethical practices, Telomir discontinued its osteoarthritis study in dogs after the safety phase due to concerns over inducing the condition. The company is now collaborating with a veterinary institution to design a study using elderly dogs naturally affected by osteoarthritis, advancing its INAD application for pets.
"As we look to 2025, Telomir remains dedicated to its mission," said Erez Aminov, Chairman and CEO. "We are pleased to have secured additional financing at a 20% premium with no warrants, providing the resources needed to continue advancing Telomir-1's development while creating value for our shareholders."
Price Action: TELO shares closed 14.10% higher at $5.18 on Friday.

Biotech

Health Care

General

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54170253&amp;newsitemid=20241223250943&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=b5586a81e66ef03f03c233e8008cee0b">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced that the European Commission (EC) has approved Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE; (ipilimumab)for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
"Colorectal cancer is the second leading cause of cancer death in Europe and patients are in need of new treatment options that delay disease progression. Approximately 5-7% of metastatic colorectal cancer patients have MSI-H/dMMR tumors and these patients are less likely to benefit from conventional chemotherapy and typically have poor prognosis outcomes," said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. "The EC's decision to approve Opdivo plus Yervoy represents a significant milestone for this patient population in the European Union and underscores our commitment to advancing treatment options."

Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and maintains $81 price target.

DA Davidson Maintains Buy on Estee Lauder Cos, Maintains $81 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.

BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Yi Chen initiates coverage on Sanara MedTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTI#NASDAQ">SMTI</a>) with a Buy rating and announces Price Target of $50.

SMTI

HC Wainwright & Co. Initiates Coverage On Sanara MedTech with Buy Rating, Announces Price Target of $50

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and maintains $70 price target.

Telsey Advisory Group Maintains Outperform on Kroger, Maintains $70 Price Target

HC Wainwright &amp; Co. analyst Andres Maldonado initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Buy rating and announces Price Target of $25.

ENGN

HC Wainwright & Co. Initiates Coverage On enGene Holdings with Buy Rating, Announces Price Target of $25

NanoViricides, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NYSE">NNVC</a>) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug.
"Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."
WHO has stated "Available virus sequences from human cases [of H5 infection] have shown some genetic markers that may reduce susceptibility to neuraminidase inhibitors (antiviral medicines such as oseltamivir) [NAIs] or endonuclease inhibitors (such as baloxavir marboxil) [PBIs]" in their updated public health assessment of recent Influenza A H5 infections, dated December 20, 2024

NNVC

NanoViricides Claims NV-387 Could Be Key in Fighting Bird Flu Pandemic

Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) today announced it has agreed to acquire Lexmark International, Inc., from Ninestar Corporation, PAG Asia Capital, and Shanghai Shouda Investment Centre in a deal valued at $1.5 billion, inclusive of assumed liabilities. This acquisition will strengthen the Xerox core print portfolio and build a broader global print and managed print services business better suited to meet the evolving needs of clients in the hybrid workplace.

Xerox to Acquire Lexmark in $1.5B Deal to Expand Print Services

Tianneng Power International (HK:0819) has released an update. Tianneng Power International Limited announced that all resolutions proposed at thei...

Tianneng Power Shareholders Greenlight Key Resolutions

Tianneng Power International (HK:0819) has released an update. Tianneng Power International Limited has announced an upcoming board meeting schedul...

Tianneng Power Schedules Crucial Financial Meeting

Tianneng Power International (HK:0819) has released an update. Tianneng Power International Limited reports a modest increase in revenue and a 9.32...

Tianneng Power Posts Profit Growth and Asset Rise

Tianneng Power International (HK:0819) has released an update. Tianneng Power International Limited has announced the appointment of Dr. Guo Yuanta...

Tianneng Power Welcomes New Board Member

Tianneng Power International (HK:0819) has released an update. Tianneng Power International Limited has announced the composition of its board of d...

Tianneng Power Unveils Board Structure and Committees

PBD: Outperforming U.S.-Only Clean Energy

Tianneng Power International (HK:0819) has released an update. Tianneng Power International Limited reported a 6.21% decline in revenue and a 14.45...

Tianneng Power Reports Mixed Financial Performance

Tianneng Power International (HK:0819) has released an update. Tianneng Power International is set to acquire a 28.57% equity interest in its subsi...

Comments

Tianneng Power Intl

Tianneng Power Intl (TIANF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga